Most recent by Rachel A. Freedman, MD, MPH
SPONSORED CONTENT
April 25, 2018
6 min read
Save
Practical considerations must guide combination treatment for older patients with advanced hormone receptor-positive breast cancer
An FDA-conducted meta-analysis of CDK4/6 inhibitor trials submitted for FDA registration showed no difference in the efficacy or tolerability of CDK4/6 inhibitors between elderly and younger patients with advanced breast cancer.